Skip to main content
SpringerLink
Log in

Intracavernous Pharmacotherapy for Erectile Dysfunction

  • Chapter
Erectile Dysfunction

Abstract

The accidental discovery of the effect of intracavernous injection of papaverine on penile erection by Virag [51], and systematic research into the effects of the α-adrenergic receptor-blocking drug phenoxybenzamine and various smooth muscle relaxing agents by Brindley [3, 5] have completely changed the treatment modalities of erectile impotence in the last decade.

This is a preview of subscription content, log in via an institution to check access.

Access this chapter

Log in via an institution
eBook
USD 16.99
Price excludes VAT (USA)
  • Available as EPUB and PDF
  • Read on any device
  • Instant download
  • Own it forever
Softcover Book
USD 16.99
Price excludes VAT (USA)
  • Compact, lightweight edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info

Tax calculation will be finalised at checkout

Purchases are for personal use only

Institutional subscriptions

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References

  1. Bähren W, Scherb WH, Gall H et al. (1988) Effects of intracavernous self-injection therapy on self-esteem and partnership in patients with chronic erectile dysfunction. Third Biennial World Meeting on Impotence, Boston, Mass, Oct. 6–9

    Google Scholar 

  2. Bénard F, Stief CG, Bosch R, Diederichs W, Lue TF, Tanagho EA (1988) Systemic infusion of epinephrine: its effect on erection. Third Biennial World Meeting on Impotence, Boston, Mass, Oct. 6–9

    Google Scholar 

  3. Brindley GS (1983) Cavernosal alpha-blockage: A new technique for investigating and treatig erectile impotence. Br J Psychiatry 143: 332–337

    Article  PubMed  CAS  Google Scholar 

  4. Brindley GS (1984) New treatment for priapism. Lancet I: 220–221

    Google Scholar 

  5. Brindley GS (1986) Pilot experiments on the actions of drugs injected into the human corpus cavernosum penis. Br J Pharmacol 87: 495–500

    Article  PubMed  CAS  Google Scholar 

  6. Buvat J, Lemaire A, Marcolin G et al. (1987) Intracavernous injection of papaverine (ICIP). Assessment of its diagnostic and therapeutic value in 100 impotent patients. World J Urol 5: 150–155

    Article  Google Scholar 

  7. Conti G (1952) L’érection du penis humain et ses bases morphologico-vasculaires. Acta Anatomica 14: 217–262

    Article  PubMed  CAS  Google Scholar 

  8. Corriere JN, Fishman IJ, Benson GS, Carlton CE (1988) Development of fibrotic penile lesions secondary to the intracorporeal injection of vasoactive agents. J Urol 140: 615–617

    PubMed  Google Scholar 

  9. De la Torre (1978) US Patent no 4. 127. 118

    Google Scholar 

  10. Diederichs W, Lue TF (1989) Reduktion der Sympathikuswirkung auf die Erektion durch Phentolamin. 41. Kongreß der Dtsch Ges für Urologie, Freiburg, 4. - 7. Okt.

    Google Scholar 

  11. Domer FR, Wessler G, Brown RL et al. (1978) Involvement of the sympathetic nervous system in the urinary bladder internal sphincter. Invest Urol 15: 404

    PubMed  CAS  Google Scholar 

  12. Earle CM, Keogh EJ, Wisniewski ZS, Tulloch GS et al. (1990) Prostaglandin El therapy for impotence, comparison with papaverine. J Urol 143: 57–59

    PubMed  CAS  Google Scholar 

  13. Ebner V von (1900) Über klappenartige Vorrichtungen in den Arterien der Schwellkörper. Anatom Anzeiger (Ergänzungsheft 7 ) 18: 79–81

    Google Scholar 

  14. Goldstein I, Payton TR, de Tejada IS, Krane RJ (1985) Pharmacologic erections: Role in the treatment of neurologic impotence. J Urol 133: 261

    Google Scholar 

  15. Hedlund H, Andersson KE (1985) Contraction and relaxation induced by some prostanoids in isolated human penile erectile tissue and cavernous artery. J Urol 134: 1245–1250

    PubMed  CAS  Google Scholar 

  16. Hwang T, Lue TF, Yang CR, Chang CL (1989) Drug-induced penile blood flow study: effect of papaverine versus prostaglandin El. J Urol 141:261 A

    Google Scholar 

  17. Hwang T, Yang CR, Wang SJ et al. (1989) Impotence evaluated by the use of prostaglandin El. J Urol 141: 1357–1359

    PubMed  CAS  Google Scholar 

  18. Ishii N, Watanabe H, Irisawa C, Kikuchi Y (1986) Therapeutic trial with prostaglandin El for organic impotence. Second World Meeting on Impotence, Prague

    Google Scholar 

  19. Ishii N, Watanabe H, Irisawa C et al. (1986) Studies on male sexual impotence. Jap J Urol 77: 954

    PubMed  CAS  Google Scholar 

  20. Ishii N, Watanabe H, Irisawa Cet al. (1989) Intracavernous injection of prostaglandin El for the treatment of erectile impotence. J Urol 141: 323–325

    PubMed  CAS  Google Scholar 

  21. Juburi AZ, O’Donnell PD (1987) Experience with a new impotence therapy: penile self-injection. J Urol 37: 208A

    Google Scholar 

  22. Jünemann K-P, Alken P (1989) Pharmacotherapy of erectile dysfunction: a review. Int J Impotence Res 1: 71–93

    Google Scholar 

  23. Jünemann K-P, Jecht E, Müller-Mattheis V et al. (1988) Offene Multicenterstudie zur Differentialdiagnostik der erektilen Dysfunktion mit einer Papaverin-PhentolaminKombination (By 023). Urologe A 27: 2–7

    PubMed  Google Scholar 

  24. Keogh EJ, Earle CM, Wisniewski ZS, Lord PJ, Tulloch AGS (1988) Comparison of vasoactive agents for impotence. Third Biennial World Meeting on Impotence, Boston, Mass Oct 6–9

    Google Scholar 

  25. Keogh EJ, Watters GR, Earle CM et al. (1989) Treatment of impotence by intrapenile injections. Am comparison of papaverine versus papaverine and phentolamine: a double-blind, crossover trial. J Urol 142: 726–728

    CAS  Google Scholar 

  26. Kiely EA, Ignotus P, Williams G (1987) Penile function following intracavernosal injection of vasoactive agents or saline. Br J Urol 59: 473–476

    Article  PubMed  CAS  Google Scholar 

  27. Kiss F (1921) Anatomisch-histologische Untersuchungen über die Erektion. Z Anat 61: 455–521

    Article  Google Scholar 

  28. Klinge E, Sjöstrand, HO (1974) Contraction and relaxation of the retractor penis muscle and the penile artery of the bull. Acta Phys Scand (Suppl) 420

    Google Scholar 

  29. Levine S, Althof S, Turner L et al. (1989) Side effects of self-administration of intracavernous papaverine and phentolamine for the treatment of impotence. J Urol 141: 54–57

    PubMed  CAS  Google Scholar 

  30. Lue TF (1989) Editorial comment on Ishii et at. (1989) Intracavernous injection of prostaglandin El. J Urol 141: 325

    Google Scholar 

  31. Lue TF, Takamura T, Schmidt RA et al. (1983) Hemodynamics of erection in the monkey. J Urol 130: 1237–1240

    PubMed  CAS  Google Scholar 

  32. Lue TF, Hellstrom WJ, McAninch JW, Tanagho EA (1986) Priapism: a refined approach to diagnosis and treatment. J Urol 136: 104–108

    PubMed  CAS  Google Scholar 

  33. Nellans RE, Leland RE, Kramer-Levien D (1987) New treatment for impotence: pharmacologic erection. Medical Aspects of Human Sexuality, March 20–28

    Google Scholar 

  34. Padma-Nathan H, Goldstein J, Azadzoi R et al. (1986) In vivo and in vitro studies on the physiology of penile erection. Semin Urol 4: 209–216

    PubMed  CAS  Google Scholar 

  35. Padma-Nathan H, Goldstein I, Payton T, Krane RJ (1987) Intracavernosal pharmacotherapy: the pharmacologic erection program. World J Urol 5: 160–165

    Article  Google Scholar 

  36. Porst H (1988) Stellenwert von Prostaglandin El (PGE1) in der Diagnostik der erektilen Dysfunktion (ED) im Vergleich zu Papaverin und Papaverin/Phentolamin bei 61 Patienten mit ED. Urologe A 27: 22–26

    PubMed  CAS  Google Scholar 

  37. Porst H (1989) Prostaglandin El bei erektiler Dysfunktion. Urologe A 28: 94–98

    PubMed  CAS  Google Scholar 

  38. Robinette MA, Moffat MJ (1986) Intracorporeal injection of papaverine and phentolamine in the management of impotence. Br J Urol 58: 692–695

    Article  PubMed  CAS  Google Scholar 

  39. Rudnick J, Weidner W (1990) Schwellkörper-Autoinjekionstherapie mit PapaverinMonosubstanz — eine mittelfristige Verlaufsbeobachtung. In: Wetterauer U, Stief CG (Hrsg) Diagnostik und Therapie der erektilen Dysfunktion mit vasoaktiven Substanzen. de Gruyter, Berlin New York, S 75–80

    Google Scholar 

  40. Schramek P, Dorninger R, Waldhauser M et al. (1990) Prostaglandin El in erectile dysfunction. Efficiency and incidence of priapism. Br J Urol 65: 68–71

    Article  PubMed  CAS  Google Scholar 

  41. Sidi AA, Chen KK (1987) Clinical experience with vasoactive intracavernous pharmacotherapy for the treatment of impotence. World J Urol 5: 156–159

    Article  Google Scholar 

  42. Sidi AA, Cameron JS, Duffy LM, Lange PH (1986) Intracavernous drug-induced erections in the management of male erectile dysfunction: experience with 100 patients. J Urol 135: 704–706

    PubMed  CAS  Google Scholar 

  43. Stackl W (1990) Prostaglandin El zur Therapie der erektilen Dysfunktion. In: Wetterauer U, Stief CG (Hrsg) Diagnostik und Therapie der erektilen Dysfunktion mit vasoaktiven Substanzen. de Gruyter, Berlin New York, S 91–96

    Google Scholar 

  44. Stackl W, Hasun R, Marberger M (1988) Intracavernous injection of prostaglandin El in impotent men. J Urol 140: 66–68

    PubMed  CAS  Google Scholar 

  45. Steffens J, Postma H, Steffens L (1988) Ergebnisse und Akzeptanz der Schwellkörperautoinjektionstherapie ( SKAT) bei organischer erektiler Dysfunktion. Urologe A 27: 14–16

    Google Scholar 

  46. Stief CG, Wetterauer U (1988) Erectile Responses to intracavernous papaverine and phentolamine: Comparison of single and combined delivery. J Urol 140: 1415–1416

    Google Scholar 

  47. Stief CG, Thon W, Scherb W et al. (1987) Zwei Jahre Erfahrungen mit der Schwellkörper-Autoinjektionstherapie ( SKAT ). Urologe A 26: 294–296

    PubMed  CAS  Google Scholar 

  48. Stief CG, Gilbert P, Wetterauer U et al. (1987) Metaraminol–ein Antidot bei SKAT-bedingter prolongierter Erektion. Urologe A 25: 164–166

    Google Scholar 

  49. Stief CG, Bähren W, Gall H, Scherb W (1988) Functional evaluation of penile hemodynamics. J Urol 139: 734–737

    PubMed  CAS  Google Scholar 

  50. Trapp JD (1987) Pharmacologic erection program for the treatment of impotence. South Med J 80: 426–427

    Article  PubMed  CAS  Google Scholar 

  51. Virag R (1982) Intracavernous injection of papaverine for erectile failure. Lancet II: 938

    Google Scholar 

  52. Virag R, Bouilly R, Daniel C, Virag H (1985) Intracavernous injection of papaverine and other vasoactive drugs: a new era in the diagnosis and treatment of impotence. In: Virag R, Virag H (eds) Proceedings of the First World Meeting on Impotence. Ceri, Paris, pp 187–194

    Google Scholar 

  53. Virag R, Daniel C, Sussman H, Bouilly P, Virag H (1986) Self-intracavernous injection of vasoactive drugs for the treatment of psychogenic and neurologic impotence (late results in 109 patients). Proc 2nd World Meeting Impotence, Prague

    Google Scholar 

  54. Watters GR, Keogh EJ, Carati CJ et al (1988) Prolonged erections following intracorporeal injection of medications to overcome impotence. Br J Urol 62: 173–175

    Article  PubMed  CAS  Google Scholar 

  55. Weiske WH (1988) Prolonged erection by vasoactive drugs. Third Biennial World Meeting on Impotence. Boston, Mass, Oct. 6–9, p 89

    Google Scholar 

  56. Wetterauer U, Zentgraf M (1988) Impotenz: Komplikationen der Autoinjektionstherapie — eine Übersicht. Akt Urol 19: 315–320

    Google Scholar 

  57. Wetterauer U, Stief CG, Sommerkamp H (1987) Intracavernous application of papaverine and phentolamine for erectile dysfunction. Experience with 110 cases. Proceedings 5th Int Forum of Andrology, Paris

    Google Scholar 

  58. Wetterauer U, Weiske WH, Stief CG, Zentgraf M (1988) Intraindividual comparison of the efficacy of the intracavernously injected single agents papaverine and phentolamine with the combination of -both. Third Biennial World Meeting on Impotence, Boston, Mass, Oct. 6–9

    Google Scholar 

  59. Wetterauer U, Koppermann U, Lühmann R, Hakenberg O, Sommerkamp H (1990) Pharmakokinetik von Papaverin und Phentolamin bei intracavernöser Applikation. 11th Int Symposium Ludwig-Boltzmann-Institut, Vienna, Febr. 22–24

    Google Scholar 

  60. Wetterauer U, Koppermann U, Bischoff R, Sommerkamp H (1990) Intraindividueller Vergleich von Prostaglandin El und einem Papaverin-Phentolamin-Gemisch zur Erektionsauslösung bei Patienten mit erektiler Dysfunktion. 11th Int Symposium Ludwig-Boltzmann-Institut, Vienna, Febr. 22–24

    Google Scholar 

  61. Williams G, Mulcahy MJ, Kiely EA (1987) Impotence: treatment by autoinjection of vasoactive drugs. Br Med J 295: 595–596

    Article  CAS  Google Scholar 

  62. Zorgniotti AW (1986) Corpus cavernosum blockade for impotence: practical aspects and results in 250 cases. J Urol 135: 306A

    Google Scholar 

  63. Zorgniotti AW, Lefleur RS (1985) Auto-injection of the corpus cavernous with a vasoactive drug combination for vasculogenic impotence. J Urol 133: 39–41

    PubMed  CAS  Google Scholar 

Download references

Authors
  1. U. Wetterauer
    View author publications

    You can also search for this author in PubMed Google Scholar

Editor information

Editors and Affiliations

  1. Klinik für Urologie, Medizinische Hochschule Hannover, Konstanty-Gutschow-Straße 8, W-3000, Hannover 61, Germany

    Udo Jonas , Walter Ferdinand Thon  & Christian Georg Stief ,  & 

Rights and permissions

Reprints and permissions

Copyright information

© 1991 Springer-Verlag Berlin Heidelberg

About this chapter

Cite this chapter

Wetterauer, U. (1991). Intracavernous Pharmacotherapy for Erectile Dysfunction. In: Jonas, U., Thon, W.F., Stief, C.G. (eds) Erectile Dysfunction. Springer, Berlin, Heidelberg. https://doi.org/10.1007/978-3-662-00986-4_19

Download citation

  • DOI: https://doi.org/10.1007/978-3-662-00986-4_19

  • Publisher Name: Springer, Berlin, Heidelberg

  • Print ISBN: 978-3-662-00988-8

  • Online ISBN: 978-3-662-00986-4

  • eBook Packages: Springer Book Archive

Publish with us

Policies and ethics

Search

Navigation